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Introduction:  
Statins are powerful hypolipaemic drugs which are proven to improve survival in patients 
with atherosclerosis. Their effects are not limited to lowering cholesterol but also include 
antiinflammatory and antioxidative properties. For these reasons, it has been postulated that 
statins may reduce mortality in critically ill patients. We aimed to investigate the association 
between statin therapy on admission and outcome from intensive care in our ICU. 
 
Methods: 
A prospective case note review of 504 consecutive admissions to Glasgow Royal Infirmary 
Intensive Care Unit (ICU) was undertaken over an 18 month period. Details of statin 
prescription, cardiovascular comorbidity and smoking status was sought from the patients’ 
case notes by hand using details of current and previous admissions, clinical letters, results of 
investigations and correspondence from the patient’s general practitioner, using agreed 
criteria. Demographic, Acute Physiology and Chronic Health Evaluation II (APACHE-II) 
score and outcome data were retrieved from the Ward Watcher system in the ICU. 
 
Results: 
Complete data were available for 444 patients. 111 (25%) of these were on statin therapy on 
admission to intensive care.See Table below for all results. All data are expressed as Mean ± 
95% Confidence Interval or Median (Interquartile Range). Differences between groups were 
tested using Chi-squared test, Mann-Whitney test and unpaired Students t-test. 
 Statin 
n=111 
No Statin 
n=333 
p 
Male (%) 76.6 63.0 0.009 
Age (years) 65.2 ± 1.93 49.7 ± 1.86 <0.001 
APACHE II  20 (15-25) 16 (11-23) <0.001 
ICU Mortality (%) 27.9 27 0.86 
Hospital Mortality (%) 40.5 31.2 0.07 
Predicted Mortality (%) 37.2 ± 3.97 28.7 ± 2.68 0.001 
Length of ICU Stay (days) 6.0 ± 1.7 5.8 ± 1.1 0.88 
Ischaemic Heart Disease (%) 69.4 17.1 <0.001 
Hypertension (%) 47.5 0.22 <0.001 
Cigarette Smoking (%) 41.4 47.4 0.27 
 
Conclusions 
Statin therapy does not significantly alter ICU or hospital mortality in our population. 
Patients on statin therapy are more likely to be older, male and also have hypertension and 
ischaemic heart disease. There are significant differences in APACHE II scores between the 
groups and predicted mortality which may suggest that patients on statins fare better than 
predicted, based upon their comorbidities. 
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